netarsudil ophthalmic (Rx)

Brand and Other Names:Rhopressa
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ophthalmic solution

  • 0.02% (0.2mg/mL)

Elevated Intraocular Pressure

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

Instill 1 drop in the affected eye(s) qDay in the evening

Also see Administration

Dosing Considerations

Contains benzalkonium chloride, which may be absorbed by soft contact lenses; remove contact lenses prior to instilling ophthalmic solution into eye(s); may reinsert contact lenses 15 minutes following its administration (see Warnings)

<18 years: Safety and efficacy not established

Next:

Adverse Effects

>10%

Hyperemia (53%)

~20%

  • Corneal verticillata
  • Instillation site pain
  • Conjunctival hemorrhage

1-10%

5-10%

  • Instillation site erythema
  • Corneal staining
  • Blurred vision
  • Increased lacrimation
  • Erythema of eyelid
  • Reduced visual acuity
Previous
Next:

Warnings

Contraindications

None

Cautions

Bacterial keratitis associated with use of multiple-dose containers of topical ophthalmic products; containers had been inadvertently contaminated by patients who had a concurrent corneal disease or a disruption of the ocular epithelial surface

Remove contact lenses prior to instilling ophthalmic solution; may reinsert lenses 15 minutes following administration

Previous
Next:

Pregnancy

Pregnancy

Data are not available on use in pregnant women to inform of any drug associated risk; however, systemic exposure to netarsudil from ocular administration is low

IV administration of netarsudil to pregnant rats and rabbits during organogenesis did not produce adverse embryofetal effects at clinically relevant systemic exposures

Lactation

No data on the presence in human milk, the effects on the breastfed infant, or the effects on milk production

Systemic exposure to netarsudil following topical ocular administration is low, and unknown whether measurable levels of netarsudil would be present in maternal milk following topical ocular administration

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Dual inhibitor of Rho kinase and the norepinephrine plasma membrane transport protein

Increases trabecular outflow

Absorption

Plasma concentration, after 8 days: 0.11 ng/mL (active metabolite)

Metabolism

Metabolized by esterases in the eye

Previous
Next:

Administration

Ocular Administration

Instill 1 drop in the affected eye(s) qDay in the evening

Missed dose

  • One missed dose: Continue with the next dose in the evening; twice a day dosing is not well tolerated and is not recommended
  • Concomitant use with other topical ophthalmic drug products to lower IOP: Administer each drug product >5 minutes apart

Storage

Unopened bottle: Store at 2-8°C (36-46°F) until opened

Open bottle: Store at 2-25°C (36-77°F) for up to 6 weeks

During shipment, bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 14 days

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.